#For patients
Written for adults considering a peptide as part of their health management.
What is tesamorelin?
Tesamorelin (Egrifta) is FDA-approved for HIV lipodystrophy. Plain-English guide to its mechanism, one approved indication, and what the Phase 3 trials found.
What BPC-157 costs in Denmark
BPC-157 has no marketing authorisation in Denmark: no official price, no pharmacy route, no reimbursement. What the grey-market reality looks like.
How Tesamorelin works: the mechanism
Tesamorelin binds GHRH receptors in the pituitary, triggers GH pulses, and raises IGF-1. Plain-English guide to the mechanism.
Tesamorelin side effects and safety data
The FDA label and phase-3 trials list injection site reactions, arthralgia, edema, and a threefold rise in new-onset dysglycemia. Here is what the data show.
What tirzepatide costs in Germany
Cash prices, GKV reimbursement rules, PKV coverage, and the AMNOG process that determines what Mounjaro costs in Germany in 2026.
What is Semax? A plain-English explainer
Semax is a synthetic neuropeptide licensed in Russia for stroke recovery and unapproved in the EU, UK, and US. Here is what the research actually shows.
Semaglutide side effects: what trials show
The STEP and SUSTAIN programmes documented semaglutide adverse events at scale. Here is what the data show, from GI effects to the thyroid boxed warning.
What is Semaglutide?
Semaglutide (Ozempic, Wegovy, Rybelsus) is a GLP-1 receptor agonist for type 2 diabetes and weight management. How it works and what the trials show.
Semaglutide in schizophrenia: HISTORI trial
Three randomised trials show semaglutide cuts weight and blood sugar in antipsychotic-treated patients without worsening psychiatric symptoms.
What is PT-141? A plain-English explainer
PT-141 (bremelanotide, brand name Vyleesi) is a melanocortin receptor agonist with one FDA-approved indication and no EU marketing authorisation.
Retatrutide: a plain-English explainer
Retatrutide is an investigational triple-receptor agonist: GLP-1, GIP, and glucagon. Phase 2 data showed up to 24% weight loss at 48 weeks. Not approved.
Semaglutide and weight in schizophrenia
A 24-week trial found semaglutide reduced body weight by 9.8% in people with schizophrenia on clozapine or olanzapine, with partial regain after stopping.